Can muscle regeneration fail in chronic inflammation: A weakness in inflammatory myopathies?

Journal of Internal Medicine

Volumn 269, Issue 3, 2011, Pages 243-257

  Loell, I ^a   Lundberg, I E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokines; Eicosanoids; Inflammation; Inflammatory myopathies; Myositis; Pathogenesis; Physical exercise; Regeneration

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; HIGH MOBILITY GROUP B1 PROTEIN; IBUPROFEN; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRE METABOLIC MYOPATHY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHRONIC INFLAMMATION; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ASSOCIATION; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE ATROPHY; MUSCLE REGENERATION; MUSCLE WEAKNESS; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PLASMACYTOID DENDRITIC CELL; POLYMYOSITIS; PRIORITY JOURNAL; RASH; REVIEW; SKELETAL MUSCLE; WEAKNESS;

CHRONIC DISEASE; CYTOKINES; EICOSANOIDS; EXERCISE; HUMANS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSITIS; REGENERATION;

EID: 79951688504     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02334.x     Document Type: Review

References (127)

1. Greenberg SA, Bradshaw EM, Pinkus JL et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65: 1782-7.
2. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15.
3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82.
4. Brouwer R, Hengstman GJ, Vree Egberts W et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60: 116-23.
5. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010; 6: 129-37.
6. Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991; 29: 498-507.
7. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med 2002; 166: 479-84.
8. Grundtman C, Bruton J, Yamada T et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 2010; 24: 570-8.
9. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865-74.
10. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990; 27: 343-56.
11. Grundtman C, Tham E, Ulfgren AK, Lundberg IE. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008; 58: 3224-38.
12. Nagaraju K, Casciola-Rosen L, Lundberg I et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824-35.
13. Greenberg SA, Pinkus JL, Pinkus GS et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664-78.
14. Fasth AE, Dastmalchi M, Rahbar A et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009; 183: 4792-9.
15. Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 2007; 18: 335-43.
16. Li YP, Reid MB. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol 2001; 13: 483-7.
17. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factors. Dev Comp Immunol 2004; 28: 487-97.
18. Collins RA, Grounds MD. The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. Studies in TNF-alpha(-/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice. J Histochem Cytochem 2001; 49: 989-1001.
19. Li YP. TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 2003; 285: C370-6.
20. Bodine SC, Latres E, Baumhueter S et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-8.
21. Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996; 55: 342-7.
22. Warren GL, Hulderman T, Jensen N et al. Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J 2002; 16: 1630-2.
23. Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 177-90.
24. Dastmalchi M, Grundtman C, Alexanderson H et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67: 1670-7.
25. Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007; 56: 674-87.
26. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4(Suppl 3): S233-42.
27. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009; 21: 224-30.
28. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-7.
29. Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003; 285: E433-7.
30. Tsujinaka T, Fujita J, Ebisui C et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97: 244-9.
31. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005; 98: 911-7.
32. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP. Role of myokines in exercise and metabolism. J Appl Physiol 2007; 103: 1093-8.
33. Keller P, Penkowa M, Keller C et al. Interleukin-6 receptor expression in contracting human skeletal muscle: regulating role of IL-6. FASEB J 2005; 19: 1181-3.
34. Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 2008; 7: 33-44.
35. White JP, Reecy JM, Washington TA et al. Overload-induced skeletal muscle extracellular matrix remodelling and myofibre growth in mice lacking IL-6. Acta Physiol (Oxf) 2009; 197: 321-32.
36. Febbraio MA, Rose-John S, Pedersen BK. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 2010; 87: 396-8.
37. Bilgic H, Ytterberg SR, Amin S et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436-46.
38. Kirman I, Vainer B, Nielsen OH. Interleukin-15 and its role in chronic inflammatory diseases. Inflamm Res 1998; 47: 285-9.
39. Sugiura T, Harigai M, Kawaguchi Y et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 2002; 14: 917-24.
40. Furmanczyk PS, Quinn LS. Interleukin-15 increases myosin accretion in human skeletal myogenic cultures. Cell Biol Int 2003; 27: 845-51.
41. Busquets S, Figueras MT, Meijsing S et al. Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med 2005; 16: 471-6.
42. Carbo N, Lopez-Soriano J, Costelli P et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer 2000; 83: 526-31.
43. Nielsen AR, Mounier R, Plomgaard P et al. Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J Physiol 2007; 584: 305-12.
44. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997; 233: 231-7.
45. Gardella S, Andrei C, Ferrera D et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001.
46. Ulfgren AK, Grundtman C, Borg K et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50: 1586-94.
47. De Mori R, Straino S, Di Carlo A et al. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol 2007; 27: 2377-83.
48. Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol 2004; 24: 4880-94.
49. Riuzzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 2006; 281: 8242-53.
50. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15-23.
51. Berlin T, Cronestrand R, Nowak J, Sonnenfeld T, Wennmalm A. Conversion of arachidonic acid to prostaglandins in homogenates of human skeletal muscle and kidney. Acta Physiol Scand 1979; 106: 441-5.
52. Prisk V, Huard J. Muscle injuries and repair: the role of prostaglandins and inflammation. Histol Histopathol 2003; 18: 1243-56.
53. Rodemann HP, Goldberg AL. Arachidonic acid, prostaglandin E2 and F2 alpha influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem 1982; 257: 1632-8.
54. Zalin RJ. The role of hormones and prostanoids in the in vitro proliferation and differentiation of human myoblasts. Exp Cell Res 1987; 172: 265-81.
55. Otis JS, Burkholder TJ, Pavlath GK. Stretch-induced myoblast proliferation is dependent on the COX2 pathway. Exp Cell Res 2005; 310: 417-25.
56. Hedenberg-Magnusson B, Ernberg M, Alstergren P, Kopp S. Pain mediation by prostaglandin E2 and leukotriene B4 in the human masseter muscle. Acta Odontol Scand 2001; 59: 348-55.
57. Tegeder L, Zimmermann J, Meller ST, Geisslinger G. Release of algesic substances in human experimental muscle pain. Inflamm Res 2002; 51: 393-402.
58. Nyberg P, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000; 27: 940-8.
59. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 1983; 308: 553-8.
60. Schafers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain 2003; 104: 579-88.
61. Bondesen BA, Jones KA, Glasgow WC, Pavlath GK. Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion. FASEB J 2007; 21: 3338-45.
62. Velica P, Bunce CM. Prostaglandins in muscle regeneration. J Muscle Res Cell Motil 2008; 29: 163-7.
63. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003; 4: 965-73.
64. Sun R, Ba X, Cui L, Xue Y, Zeng X. Leukotriene B4 regulates proliferation and differentiation of cultured rat myoblasts via the BLT1 pathway. Molecules and Cells 2009; 27: 403-8.
65. Xu S, Lu H, Lin J, Chen Z, Jiang D. Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol Int 2010; 30: 1183-9.
66. Islam SATS, Hess C, Medoff BD et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 2006; 15: 444-53.
67. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 123-34.
68. Payan DG, Missirian-Bastian A, Goetzl EJ. Human T-lymphocyte subset specificity of the regulatory effects of leukotriene B4. Proc Natl Acad Sci U S A 1984; 81: 3501-5.
69. Leppert D, Hauser SL, Kishiyama JL, An S, Zeng L, Goetzl EJ. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J 1995; 9: 1473-81.
70. Bacon KB, Camp RD, Cunningham FM, Woollard PM. Contrasting in vitro lymphocyte chemotactic activity of the hydroxyl enantiomers of 12-hydroxy-5, 8, 10, 14-eicosatetraenoic acid. Br J Pharmacol 1988; 95: 966-74.
71. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 2005; 102: 17501-6.
72. Hedenberg-Magnusson B, Ernberg M, Alstergren P, Kopp S. Effect on prostaglandin E2 and leukotriene B4 levels by local administration of glucocorticoid in human masseter muscle myalgia. Acta Odontol Scand 2002; 60: 29-36.
73. Studynkova JT, Kuchen S, Jeisy E et al. The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. Clin Exp Rheumatol 2004; 22: 395-402.
74. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
75. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
76. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84: 209-38.
77. Bakkar N, Wang J, Ladner KJ et al. IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol 2008; 180: 787-802.
78. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-99.
79. Wang H, Hertlein E, Bakkar N et al. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007; 27: 4374-87.
80. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 2003; 60: 993-7.
81. Jung YO, Cho ML, Kang CM et al. Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. Immunol Lett 2007; 109: 21-7.
82. Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 2004; 7: 265-9.
83. Fernandez-Celemin L, Pasko N, Blomart V, Thissen JP. Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 2002; 283: E1279-90.
84. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin Jr AS. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-6.
85. Jobin C, Bradham CA, Russo MP et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999; 163: 3474-83.
86. di MeglioP, Ianaro A, Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 2005; 52: 951-8.
87. Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 2006; 8: R86.
88. Barton ER, Morris L, Kawana M, Bish LT, Toursel T. Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 2005; 32: 751-60.
89. Hnia K, Gayraud J, Hugon G et al. L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 2008; 172: 1509-19.
90. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep 2001; 3: 334-45.
91. Dastmalchi M, Alexanderson H, Loell I et al. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 2007; 57: 1303-10.
92. Nagaraju K, Raben N, Loeffler L et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000; 97: 9209-14.
93. Salomonsson S, Grundtman C, Zhang SJ et al. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve 2009; 39: 674-82.
94. Alexanderson HBJ, Alemo Munters L, Dastmalchi M, Lundberg IE. Philadelphia, 2009.
95. Ciciliot S, Schiaffino S. Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr Pharm Des 2010; 16: 906-14.
96. Grounds MD. Age-associated changes in the response of skeletal muscle cells to exercise and regeneration. Ann N Y Acad Sci 1998; 854: 78-91.
97. Bodine-Fowler S. Skeletal muscle regeneration after injury: an overview. J Voice 1994; 8: 53-62.
98. Schiaffino S, Sandri M, Murgia M. Activity-dependent signaling pathways controlling muscle diversity and plasticity. Physiology (Bethesda) 2007; 22: 269-78.
99. Tajbakhsh S. Skeletal muscle stem cells in developmental versus regenerative myogenesis. J Intern Med 2009; 266: 372-89.
100. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1173-87.
101. Karalaki M, Fili S, Philippou A, Koutsilieris M. Muscle regeneration: cellular and molecular events. In Vivo 2009; 23: 779-96.
102. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-98.
103. Dion E, Cherin P, Payan C et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29: 1897-906.
104. Loell I, Helmers SB, Dastmalchi M et al. Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies - evident in chronic but not in untreated newly diagnosed patients. Clin Physiol Funct Imaging 2011; 31: 18-25.
105. Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, De Bock V, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol 1995; 78: 629-37.
106. Hasselgren PO, Fischer JE. Counter-regulatory hormones and mechanisms in amino acid metabolism with special reference to the catabolic response in skeletal muscle. Curr Opin Clin Nutr Metab Care 1999; 2: 9-14.
107. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287: E591-601.
108. Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999; 2: 201-5.
109. Hasselgren PO, Alamdari N, Aversa Z, Gonnella P, Smith IJ, Tizio S. Corticosteroids and muscle wasting: role of transcription factors, nuclear cofactors, and hyperacetylation. Curr Opin Clin Nutr Metab Care 2010; 13: 423-8.
110. Dolan-O'keefe M, Nick HS. Inhibition of cytoplasmic phospholipase A2 expression by glucocorticoids in rat intestinal epithelial cells. Gastroenterology 1999; 116: 855-64.
111. Croxtal JD, Newman SP, Choudhury Q, Flower RJ. The concerted regulation of cPLA2, COX2, and lipocortin 1 expression by IL-1beta in A549 cells. Biochem Biophys Res Commun 1996; 220: 491-5.
112. Ziltener JL, Leal S, Fournier PE. Non-steroidal anti-inflammatory drugs for athletes: an update. Ann Phys Rehabil Med 2010; 53: 278-82.
113. Mackey AL, Kjaer M, Dandanell S et al. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl Physiol 2007; 103: 425-31.
114. Mendias CL, Tatsumi R, Allen RE. Role of cyclooxygenase-1 and -2 in satellite cell proliferation, differentiation, and fusion. Muscle Nerve 2004; 30: 497-500.
115. Bondesen BA, Mills ST, Pavlath GK. The COX-2 pathway regulates growth of atrophied muscle via multiple mechanisms. Am J Physiol Cell Physiol 2006; 290: C1651-9.
116. Alexanderson H, Stenstrom CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29: 295-301.
117. Alexanderson H, Dastmalchi M, Esbjornsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007; 57: 768-77.
118. Wiesinger GF, Quittan M, Aringer M et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37: 196-200.
119. Wiesinger GF, Quittan M, Graninger M et al. Benefit of 6months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998; 37: 1338-42.
120. Wiesinger GF, Quittan M, Nuhr M et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil 2000; 81: 1-5.
121. Chung YL, Alexanderson H, Pipitone N et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum-Arthritis Care Res 2007; 57: 694-702.
122. Alexanderson H. Exercise effects in patients with adult idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009; 21: 158-63.
123. Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports 2007; 17: 580-7.
124. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-406.
125. Gielen S, Adams V, Mobius-Winkler S et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 861-8.
126. Batista Jr ML, Rosa JC, Lopes RD et al. Exercise training changes IL-10/TNF-alpha ratio in the skeletal muscle of post-MI rats. Cytokine 2010; 49: 102-8.
127. Kramer HF, Goodyear LJ. Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. J Appl Physiol 2007; 103: 388-95.